表紙
市場調査レポート

化膿レンサ球菌感染症 : パイプライン分析

Streptococcus pyogenes Infections - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 279451
出版日 ページ情報 英文 46 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
化膿レンサ球菌感染症 : パイプライン分析 Streptococcus pyogenes Infections - Pipeline Review, H2 2016
出版日: 2016年07月20日 ページ情報: 英文 46 Pages
概要

化膿レンサ球菌感染症とは、ストレプトコッカス・ピオゲネスというグラム陽性球菌によって起こる感染症であり、感染部分の激しい痛み、腫れ、発赤、発熱、めまい、呼吸困難、危険レベルへの血圧低下、弱脈、速脈などの症状があります。抗生剤の投与、健康的な生活習慣などの治療法があります。

当レポートでは、世界における化膿レンサ球菌感染症治療薬のパイプラインについて取り上げ、現在の開発パイプラインの状況や最新動向、薬剤プロファイル、主要企業および彼らが開発中の製品のレビューなどをお届けいたします。

目次

イントロダクション

  • 分析範囲

化膿レンサ球菌感染症の概要

治療薬の開発

  • 化膿レンサ球菌感染症向けパイプライン製品:概要
  • 化膿レンサ球菌感染症向けパイプライン製品:比較分析

化膿レンサ球菌感染症:開発中の治療薬:企業別

化膿レンサ球菌感染症:開発中の治療薬:大学・研究機関別

化膿レンサ球菌感染症:パイプライン製品の概況

  • 初期段階の製品

化膿レンサ球菌感染症:開発中の製品:企業別

化膿レンサ球菌感染症:開発中の製品:大学・研究機関別

化膿レンサ球菌感染症:治療薬開発に従事している企業

  • Absynth Biologics Limited
  • Aureogen Biosciences, Inc.
  • GlaxoSmithKline Plc
  • Helix BioMedix, Inc.
  • 大日本住友製薬
  • Wellstat Vaccines, LLC

化膿レンサ球菌感染症:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • BMY-28117
  • HB-1345
  • SM-295291
  • SM-369926
  • Small Molecules to Inhibit DHFR for Infectious Diseases
  • Small Molecules to Inhibit PolC for Gram-Positive Bacterial Infections
  • streptococcus serotype A vaccine
  • streptococcus polysaccharide serotype A vaccine
  • streptococcus pyogenes vaccine (30-valent)
    • 製品概要
    • 作用機序
    • R&Dの進捗

休止状態のプロジェクト

製品開発のマイルストーン

  • 注目のニュース・プレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8241IDB

Summary

Global Markets Direct's, 'Streptococcus pyogenes Infections - Pipeline Review, H2 2016', provides an overview of the Streptococcus pyogenes Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Streptococcus pyogenes Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Streptococcus pyogenes Infections and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Streptococcus pyogenes Infections
  • The report reviews pipeline therapeutics for Streptococcus pyogenes Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Streptococcus pyogenes Infections therapeutics and enlists all their major and minor projects
  • The report assesses Streptococcus pyogenes Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Streptococcus pyogenes Infections

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Streptococcus pyogenes Infections
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Streptococcus pyogenes Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Streptococcus pyogenes Infections Overview
  • Therapeutics Development
    • Pipeline Products for Streptococcus pyogenes Infections - Overview
    • Pipeline Products for Streptococcus pyogenes Infections - Comparative Analysis
  • Streptococcus pyogenes Infections - Therapeutics under Development by Companies
  • Streptococcus pyogenes Infections - Therapeutics under Investigation by Universities/Institutes
  • Streptococcus pyogenes Infections - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Streptococcus pyogenes Infections - Products under Development by Companies
  • Streptococcus pyogenes Infections - Products under Investigation by Universities/Institutes
  • Streptococcus pyogenes Infections - Companies Involved in Therapeutics Development
    • Absynth Biologics Limited
    • AstraZeneca Plc
    • Emergent BioSolutions Inc.
    • Helix BioMedix, Inc.
    • Sumitomo Dainippon Pharma Co., Ltd.
    • Wellstat Vaccines, LLC
  • Streptococcus pyogenes Infections - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ATx-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AZ-6142 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EV-035 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HB-1345 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SM-295291 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SM-369926 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit DHFR for Infectious Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit PolC for Gram-Positive Bacterial Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Streptococcus pyogenes (30-valent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Streptococcus pyogenes vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Streptococcus pyogenes vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Streptococcus pyogenes vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Streptococcus pyogenes Infections - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Streptococcus pyogenes Infections, H2 2016
  • Number of Products under Development for Streptococcus pyogenes Infections - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Streptococcus pyogenes Infections - Pipeline by Absynth Biologics Limited, H2 2016
  • Streptococcus pyogenes Infections - Pipeline by AstraZeneca Plc, H2 2016
  • Streptococcus pyogenes Infections - Pipeline by Emergent BioSolutions Inc., H2 2016
  • Streptococcus pyogenes Infections - Pipeline by Helix BioMedix, Inc., H2 2016
  • Streptococcus pyogenes Infections - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016
  • Streptococcus pyogenes Infections - Pipeline by Wellstat Vaccines, LLC, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Streptococcus pyogenes Infections - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Streptococcus pyogenes Infections, H2 2016
  • Number of Products under Development for Streptococcus pyogenes Infections - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top